tHEORetically Speaking
Avsnitt

Weekly News Roundup — Biosimilar Policy Changes, mRNA Leadership Shifts, and Rare Disease Market Growth

tHEORetically Speaking
Dela

This week’s tHEORetically Speaking News Roundup covers the FDA’s new guidance aimed at streamlining biosimilar development and reducing drug costs, leadership changes at BioNTech as its founders step down to launch a new mRNA venture, and projections that the global rare disease drug market could surpass $400 billion by 2032. We also explore the FDA’s launch of a new unified adverse event monitoring platform designed to modernize safety surveillance and improve transparency. 

Tune in for this concise recap of the key developments shaping the life sciences, HEOR, and market access landscape. 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör HealthEconomics.com. Innehållet i podden är skapat av HealthEconomics.com och inte av, eller tillsammans med, Poddtoppen.